Beth Israel Deaconess Medical Center

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Beth Israel Deaconess Medical Center sits in the top decile of US sponsors by registered trial count (#75 of 15,742 sponsors by registered trial count).

488 total trials 66 currently recruiting 321 completed early-phase tilt top decile by trial count

Beth Israel Deaconess Medical Center: 488 sponsored US clinical trials, 66 recruiting.

Beth Israel Deaconess Medical Center sponsors 488 registered US clinical trials on ClinicalTrials.gov, 66 of them currently recruiting, and 321 completed. 45 of these trials are in Phase 3-4 (later-stage) and 144 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 8 trials.

Top-decile sponsor footprint

Beth Israel Deaconess Medical Center ranks in the top decile of sponsors by registered trial count (#75 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 51/100

321 of 380 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (84.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

488 total, page 4 of 10

COMPLETED NA

PooR Embryo Yield Cleavage Stage Versus blaStocyst Embryo Transfer (PILOT STUDY)

NCT03764865
COMPLETED Phase 4

IV Ketorolac on Platelet Function Post-Cesarean Delivery

NCT03805607
TERMINATED

CNAP vs IABP in Pregnant Women With Placenta Accreta

NCT04671680
TERMINATED

Esophageal Pressure Measurements During One-lung Ventilation

NCT04725318
TERMINATED Early Phase 1

Effect of a Low FODMAP Diet on SIBO Breath Test Positivity

NCT04627727
COMPLETED Phase 2

SH-DS01 on Fecal Metagenomic Stability

NCT04598295
COMPLETED NA

Feasibility Electrical Stimulation Study for Visual Hallucinations

NCT04870710
COMPLETED Phase 4

Prophylactic Antibiotics in Admitted Cirrhotics

NCT04218695
TERMINATED Phase 4

Crofelemer for Functional Diarrhea

NCT04486326
COMPLETED Phase 4

Novel Insight Into Migraine Pathophysiolgy and Galcanezumab Mechanisms of Action

NCT04271202
COMPLETED

Safety Assessment of Femoropopliteal Endovascular Treatment With PAclitaxel-coated Devices (SAFE-PAD Study)

NCT04496544
COMPLETED Phase 2

Zafirlukast in Treatment of Marker Relapsed Ovarian Cancer

NCT04339140
COMPLETED NA

A Study on Prevalence, Protection and Recovery From COVID-19 in Seasoned Yoga Practitioners in Comparison to Age and Gender Matched Controls

NCT04498442
COMPLETED Phase 4

Suvorexant and Sleep/Delirium in ICU Patients

NCT04092894
COMPLETED NA

Dexmedetomidine After Cesarean for the Treatment of Nausea and Shivering

NCT03370562
TERMINATED NA

Laser Treatment for Vulvar Lichen Sclerosus

NCT04134494
COMPLETED Phase 2

Take Off Pounds After Stroke Trial (TOPS)

NCT03815214
TERMINATED NA

DAMP-Mediated Innate Immune Failure and Pneumonia After Trauma - the Harvard-Longwood (HALO) Campus Area Consortium

NCT03993002
TERMINATED NA

Temporal Interference Brain Stimulation

NCT03747601
COMPLETED NA

Inner Engineering Online (IEO) Intervention for a Specific Company Employee Program

NCT04126564
COMPLETED Early Phase 1

The PATHFINDER Study: A Feasibility Trial

NCT04016740
TERMINATED Phase 4

Avoiding Neuromuscular Blockers to Reduce Complications

NCT03962725
COMPLETED NA

Neurological Impacts of Artificial Sweeteners in the Context of Diet Sodas

NCT04048681
COMPLETED NA

Mind Body Therapy for the Treatment of Chronic Pain

NCT04039139
COMPLETED Phase 2

The Use of Dantrolene to Improve Analgesia in Posterior Lumbar Surgery

NCT03762109
COMPLETED NA

The Digital Incentive Spirometer (DIS): Improving Adherence to Incentive Spirometry

NCT03686631
COMPLETED

Electrical Impedance Tomography for the Assessment of Neurological Disease

NCT05238038
COMPLETED NA

Effects of Low FODMAP Diet on Leaky Gut

NCT04526808
COMPLETED NA

Computer Aided Detection of Polyps in the Colon

NCT03925337
COMPLETED NA

Using Transcranial Magnetic Stimulation (TMS) to Understand 'Negative' Symptoms of Schizophrenia

NCT03648268
COMPLETED NA

High Definition Colonoscopy (HDC) vs. Dye Spraying Chromo-colonoscopy (DSC) in Screening Patients With Long-standing Inflammatory Bowel Disease (IBD)

NCT04191655
TERMINATED Phase 2

Secukinumab for NLD (Cosentyx) in Patients With Necrobiosis Lipoidica Diabeticorum (NLD)

NCT03791060
COMPLETED NA

Inner Engineering Yoga Program on Short and Long Term Health Effects (ISHA-Impact): A Longitudinal Study

NCT04189146
TERMINATED Phase 2

Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma

NCT03782064
COMPLETED NA

Wellness Tool in Anesthesia Providers

NCT03844308
TERMINATED NA

Treadmill Exercise in Metabolic Syndrome

NCT03435315
COMPLETED NA

Mindful Steps: Promoting Physical Activity

NCT03003780
COMPLETED NA

Virtual Reality in the Operating Room

NCT03614325
TERMINATED Early Phase 1

Open-Label Placebo for Functional Dyspepsia

NCT03745781
COMPLETED Phase 2

Thiamine as Adjunctive Therapy for Diabetic Ketoacidosis

NCT03717896
TERMINATED

Observational Study to Evaluate Peripheral IntraVenous Analysis (PIVA) in Euvolemic, Hypovolemic, and Hypervolemic Emergency Department Patients

NCT03736421
TERMINATED NA

Traxi Panniculus Retractor for Cesarean Delivery

NCT03651076
COMPLETED NA

Improving Safety of Transitions to Skilled Nursing Care Using Videoconferencing

NCT03832257
COMPLETED

Imaging Markers of Subclinical Cardiotoxicity in Breast Cancer

NCT02666378
COMPLETED Phase 2

Thiamine as a Renal Protective Agent in Septic Shock

NCT03550794
COMPLETED Phase 2

IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3

NCT03401073
COMPLETED Phase 2

Pilot Study of Rosuvastatin and Enoxaparin Thromboprophylaxis Following Ovarian Cancer Surgery (O-STAT Study)

NCT03532139
COMPLETED

Validation of the REPS Prediction Tool

NCT03585400
COMPLETED

Provider Variability in the Use of Neuromuscular Blocking Drugs and Reversal

NCT03585348
COMPLETED NA

Kidney Paired Donation Video-Based Education Trial

NCT03013829
← Previous Page 4 of 10 Next →

Phase Distribution

PhaseTrial count
Phase 1 53
Phase 2 91
Phase 3 13
Phase 4 32

Therapeutic Areas

Breast Cancer 8
Obesity 7
Hypertension 6
Sleep 4
Schizophrenia 4
Schizoaffective Disorder 3
Sleep Deprivation 3
Parkinson's Disease 3
Respiratory Failure 3
Insomnia 3

What is open in the Beth Israel Deaconess Medical Center pipeline

66 recruiting of 488 indexed (14% open); 321 completed (66%).

Phase mix: 45 late (III/IV) vs 144 early (I/II) (early-phase heavy).

Top condition: Breast Cancer (8 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Beth Israel Deaconess Medical Center: open-pipeline peers nationwide

Peers matched on 488 registered trials and 14% open enrollment, not the therapeutic-area sidebar.

Beth Israel Deaconess Medical Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 8%10%12%14%16%18% Total trials Recruiting share Beth Israel Deaconess Medical CenterNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Fred Hutchinson Cancer CenterNational Heart, Lung, and Blood Institute (NHLBI)H. Lee Moffitt Cancer Center and Research InstituteCase Comprehensive Cancer CenterWayne State UniversityUniversity of MichiganAlbany Medical College
Beth Israel Deaconess Medical Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Beth Israel Deaconess Medical Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 488 trials (± recruiting share)

Sponsors near 14% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Beth Israel Deaconess Medical Center page

488 registered trials is a research-attention snapshot, not an endorsement of Beth Israel Deaconess Medical Center or any single study.

  • 66 of Beth Israel Deaconess Medical Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Breast Cancer is the condition Beth Israel Deaconess Medical Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Beth Israel Deaconess Medical Center pipeline card: 488 registered trials from official public datasets.Report a data error.